The largest database of trusted experimental protocols

Peritoneal Dialysis

Peritoneal Dialysis: A form of dialysis in which the patient's peritoneum is used as the dialyzing membrane.
During the process, a sterile dialysis solution is introduced into the peritoneal cavity and allowed to remain there for a period of time so that the waste products can diffuse from the blood into the dialysate.
This type of dialysis is often used for patients with end-stage renal disease, as it can be performed at home and allows for more frequent dialysis sessions.
Optimizing peritoneal dialysis research is crucial for improving patient outcomes, and tools like PubCompar.ai can help researchers effortlessly locate, compare, and analyze the latest protocols from literature, preprints, and patents to identify the best dialysis products and procedures.

Most cited protocols related to «Peritoneal Dialysis»

The MOST is a prospective epidemiological study of individuals aged 50 to 79 years; its goal is to identify risk factors for incident symptomatic knee OA and progressive OA in a sample with OA or at high risk of developing disease. Those considered at high risk included persons who were overweight or obese, those with knee pain, aching or stiffness on most of the last 30 days, a history of knee injury that made it difficult to walk for at least 1 week, or previous knee surgery. High risk for obesity was defined based on persons who weighed more than the Framingham Study median weight for their age and sex-specific group (based on Felson, et al9 (link)). For example, weight cutoffs for women: for age 50–59 years, 154 lbs; 60–69 years, 151 lbs; and for 70–79 years, 148 lbs. Weight cutoffs for men: 50–59 years, 194 lbs; 60–69 years, 187 lbs; and 70–79 years, 182 lbs. Weight was measured without shoes and heavy jewelry and in standard gown or lightweight clothing. Height was measured using a stadiometer without shoes.
All subjects were recruited from 2 US communities, Birmingham, Alabama, and Iowa City, Iowa, through mass mailing of letters and study brochures, supplemented by media and community outreach campaigns. Each center also recruited ethnic minorities according to their representation in the recruitment population.
This research was in compliance with the Helsinki Declaration, and the study protocol was approved by institutional review boards at the University of Iowa, University of Alabama, Birmingham, University of California, San Francisco, and Boston University Medical Campus. Participants all provided written informed consent.
Subjects were excluded if they screened positive for rheumatoid arthritis10 (link), had ankylosing spondylitis, psoriatic arthritis or Reiter's syndrome, had problems with kidneys that resulted in their need for hemo- or peritoneal dialysis, had a history of cancer (except for nonmelanoma skin cancer), bilateral knee replacement surgery or inability to walk without the help of another person or walker, or were planning to move out of the area in the next 3 years.
Publication 2008
Ankylosing Spondylitis Arthritis, Psoriatic Cancer of Skin Ethics Committees, Research Ethnic Minorities Kidney Knee Knee Injuries Knee Replacement Arthroplasty Malignant Neoplasms Obesity Operative Surgical Procedures Pain Peritoneal Dialysis Reiter Syndrome Walkers Woman
We defined hospitalists as physicians in general internal medicine who had at least five evaluation-and-management billings in a given year and generated at least 90% of their total evaluation-and-management billings in the year from services to hospital inpatients (Fig. 1). Since our source of data is a 5% sample, these five evaluation-and-management billings represent 100 or more charges to Medicare patients. Using inpatient evaluation-and-management billing codes (Current Procedural Terminology [CPT] codes 99221–99223, 99231–99233, and 99251–99255) and outpatient evaluation-and-management billing codes (CPT codes 99201–99205, 99211–99215, and 99241–99245), we calculated the percentage of each physician’s evaluation-and-management claims that were generated from services provided to hospitalized patients.
We analyzed the effect of different cutoff points according to the percentage of evaluation-and-management charges generated from care provided to hospitalized patients (≥80% vs. ≥90%) and according to the minimum number of evaluation-and-management charges in a given year in the 5% sample of Medicare data (≥5 vs. ≥10) in the algorithm to identify hospitalists. We tested the algorithm in a validation set of 57 hospitalists and 172 physicians in traditional non–hospital-based general internal medicine (hereafter referred to as nonhospitalists) employed in 2006 at seven hospitals. These hospitals were located in California (University of California, Los Angeles, Medical Center), Michigan (Wayne State University Detroit Medical Center), Virginia (Hospital Corporation of America [HCA]–affiliated hospitals in Richmond, including Henrico Doctors’ Hospital, John Randolph Medical Center, HCA Retreat Hospital, Johnston Willis Hospital, and Chippenham Hospital), Wisconsin (Sinai Samaritan Medical Center), and Texas (University of Texas Medical Branch, Clear Lake Regional Medical Center, and University of Texas Health Science Center at San Antonio). The algorithm requiring a minimum of 5 evaluation-and-management charges per physician in a given year and the algorithm requiring 10 or more such charges, with both requiring that 90% or more of the charges represent the care of hospitalized patients, had a sensitivity of 84.2% and 71.9%, a specificity of 96.5% and 97.1%, and a positive predictive value of 88.9% and 89.1%, respectively. The algorithm requiring 5 or more evaluation-and-management charges and the algorithm requiring 10 or more such charges, with both requiring that 80% or more of the charges represent the care of hospital inpatients, had a sensitivity of 87.7% and 73.7%, a specificity of 93.0% and 94.2%, and a positive predictive value of 80.6% and 80.8%, respectively. The sensitivities of the four algorithms were very similar (91.1%, 88.9%, 91.1%, and 88.9%, respectively) when applied to 45 hospitalists in two hospitalist groups serving community hospitals in the Houston and Austin metropolitan areas. We selected the algorithm requiring at least five evaluation-and-management charges with at least 90% of such charges generated from the care of hospital inpatients because the sensitivity (84.2%) and positive predictive value (88.9%) were acceptable.
We also evaluated the specificity of the algorithm by assessing whether hospitalists in general internal medicine identified by the algorithm submitted claims for procedures that are not usually performed by general internists; these procedures included colonoscopy, upper endoscopy, liver biopsy, hemodialysis, peritoneal dialysis, kidney biopsy, bronchoscopy, and cardiac catheterization. In 1995, the proportion of physicians identified as hospitalists who billed for one or more of these procedures was 14.9%; this percentage decreased to 2.3% in 2006. In some analyses, we also calculated the percentage of physicians in other specialties for whom more than 90% of evaluation-and-management billing codes were generated from services provided to hospitalized patients.
Publication 2009
austin Biopsy Bronchoscopy Catheterizations, Cardiac Colonoscopy Endoscopy Hemodialysis Hospitalists Hospitalization Hypersensitivity Inpatient Kidney Liver Outpatients Patients Peritoneal Dialysis Physicians
SPMs were extracted from plasma or serum samples and effluents from peritoneal dialysis (PD) using solid phase extraction (SPE) (Rund et al., 2017 (link)). In the first step a mixture of 20 deuterated IS (20 nM each, including 2H5-RvD1, 2H5-RvD2, 2H5-LXA4, 2H4-LTB4, and 2H4-9,10-DiHOME), antioxidant mixture (0.2 mg/mL BHT, 100 μM indomethacin, 100 μM soluble epoxide hydrolase inhibitor trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (t-AUCB) in MeOH) were added to 500 μL of plasma/serum or 1,200 μL of PD exudates. Then 1,400 μL ice-cold MeOH (3,360 μL for PD exudates) were added for protein precipitation (at least 30 min at −80°C). Following centrifugation, the supernatant was evaporated under a gentle nitrogen stream to <50% MeOH, diluted with 0.1 M disodium hydrogen phosphate buffer (pH 5.5) and loaded onto the preconditioned SPE column (Bond Elut Certify II, 200 mg, 3 mL; Agilent, Waldbronn, Germany). Oxylipins were eluted with ethyl acetate/n-hexane (75/25, v/v) containing 1% acetic acid. After evaporation to dryness in a vacuum concentrator (30°C, 1 mbar, ca. 60 min; Christ, Osterode, Germany) sample extracts were reconstituted in 50 μL MeOH containing 40 nM 1-(1-(ethylsulfonyl)piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea as IS 2. Injection volume was 5 μL; for samples with low SPM content a second (10 μL) injection was used for SPM quantification.
Full text: Click here
Publication 2019
4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acid Acetic Acid Antioxidants Benzoic Acid Buffers Centrifugation Cold Temperature Epoxide hydrolase ethyl acetate Exudate Indomethacin Leukotriene B4 lipoxin A4 n-hexane Nitrogen Oxylipins Peritoneal Dialysis Plasma Proteins Serum sodium phosphate, dibasic Solid Phase Extraction Urea Vacuum
We screened a total of 1736 individuals identified as incident dialysis patients by dialysis staff of which, 943 (54.3%) met eligibility criteria. Those with either a pacemaker (n = 89) or an automatic implanatable cardioverter defibrillator (n = 70) at time of screening were ineligible to participate in the study in addition to other reasons such as nursing home residents, inability to consent, history of recent cancer and history of peritoneal dialysis or transplantation. A total of 574 participants (61% of 943) were consented into the study with 402 completing the baseline cardiac evaluation. The median follow-up time was 1.78 years (range 0–5.43) with 52 participants who underwent kidney transplantation, 25 who transferred to peritoneal dialysis, and 106 who died as of July 31, 2014.
The PACE study population is predominantly younger and comprised of a larger proportion of African Americans than described in the national Comprehensive Dialysis Study (CDS) or the USRDS (Table 4) [1 ,85 (link)]. In Table 5, the baseline demographic and clinical characteristics are shown for the study population enrolled. The baseline characteristics of the cardiac measures, laboratory tests and medications are also provided for those who have completed the initial study visit with the detailed cardiac evaluation.

PACE study population and comparison to incident US dialysis cohorts

Dialysis study
PACE
CDS*
USRDS*
Time period
2009-2012
2005-2007
2008
Incident population, n5741646110,175
African American66%28%28.8%
Mean age, yrs566062.8
Younger age <65 years73%61.8%52.8%
Diabetes53%52.6%44.9%
Mean BMI, kg/m229.329.828.4
Male54%55.1%57.6%
Nutritional assessment, n402361None
Follow-upAnnual in-person clinical evaluations semi-annual phone interviewsPassivePassive
Cardiac evaluationSignal averaged ECGNoneNone
Echocardiogram
Cardiac CT calcium and angiography
Pulse wave velocity
Ankle brachial index
Hospitalizations/MortalityAdjudicatedPassivePassive
Baseline specimen collection402269None
Follow-up specimen collectionYesNoneNone

*CDS-Comprehensive Dialysis Study 1646 completed phone interview; USRDS- United States Renal Data Systems.

Baseline demographic and clinical characteristics of all enrolled PACE participants (n = 574) and completed cardiovascular study visit (n = 402)

Characteristics
All PACE participants
Completed cardiovascular visit*
Demographic
Male, n (%)319 (56)233 (59)
African-American, n (%)397 (69)288 (72)
Age in years, mean ± SD56 (13.5)55 (13.2)
Education, % graduated high school62248 (63)
Employment, % employed1247 (12)
Marital status, % married3129
Dialysis characteristics
Three times a week dialysis, n (%)566 (98.6)397 (98.8)
Three to four hour dialysis session, n (%)505 (88.0)353 (87.8)
Polyflux membrane, n (%)446 (77.7)306 (86.4)
Arteriovenous fistula access, n (%)163 (28.7)122 (30.3)
Self reported
Smoking, % ever smoker5960
Body mass index kg/m2, mean ± SD29.4 (7.9)29.3 (7.8)
CVD, % diagnosed4445
CHF, % diagnosed2325
Diabetes, % diagnosed5455
Cardiovascular study visit
Systolic blood pressure mmHg, mean ± SDn/a137 (25)
Diastolic blood pressure mmHg, mean ± SDn/a75 (15)
Waist to hip ration/a0.95 (0.08)
Frailty, % diagnosedn/a40
Average literacy, meann/aGrade 8
Cognitively impaired, % diagnosedn/a14
Depression, % diagnosedn/a17
Medications use
Betablocker, %n/a58
ACEI/ARB, %n/a44
Calcium channel blocker, %n/a60
Statins, %n/a52
Intradialytic labs
Ionized calcium mean ± SD. mmol/Ln/a1.15 (0.07)
Magnesium mean ± SD, mg/dLn/a1.76 (0.24)

*Cardiovascular study visits were conducted at the Institute for Clinical and Translational Research and the Cardiology Research Laboratory.

Full text: Click here
Publication 2015
African American Arm, Upper Blood Pressure Calcium, Dietary Cardiovascular System Defibrillators Dialysis Eligibility Determination Fistula, Arteriovenous Heart Implantable Defibrillator Kidney Kidney Transplantation Magnesium Malignant Neoplasms Nutrition Assessment Pacemaker, Artificial Cardiac Patients Peritoneal Dialysis Pharmaceutical Preparations Pressure, Diastolic Tissue, Membrane Transplantation Youth
Participants will be eligible for inclusion if they (1) have CKD (glomerular filtration rate (GFR) < 60 ml/min per 1.73 m2) stages 2 to 5, and (2) ages of 18 to 74 years. Patients undergoing hemodialysis (HD) or peritoneal dialysis (PD) will be also invited to participate. The study is designed to use a population control as reference group. Eligible controls will be asymptomatic subjects without CKD. Participants will be excluded for any of the following reasons: (1) had prior CVD, (2) received a kidney transplant, (3) had a life-threatening disease, such as cancer, (4) underwent previous carotid artery surgery, or (5) have an ABI < 0.7 and/or a carotid artery stenosis greater than 75% at baseline.
We will use the Modification of Diet in Renal Disease Study (MDRD) and the Chronic Kidney disease Epidemiology Collaboration (CKD-EPI) equations to estimate the GFR to classify patients into the different stages of CKD [25 (link),26 (link)]. Patients switching stage or dialytic modality in the follow-up of this study will be considered and these data will be registered at each visit. Only patients who switch to kidney transplant will be excluded from the follow-up. Enrollment will be stratified by hospital according to the prevalence of CKD patients in each stage, in order to obtain a sample in which all Spanish regions would be represented. Details about centers and geographical distribution can be seen at the website of the NEFRONA study http://www.nefrona.es.
Full text: Click here
Publication 2010
Carotid Stenosis Common Carotid Artery Dialysis Dietary Modification Glomerular Filtration Rate Hemodialysis Hispanic or Latino Kidney Diseases Kidney Transplantation Malignant Neoplasms Operative Surgical Procedures Patients Peritoneal Dialysis Vision

Most recents protocols related to «Peritoneal Dialysis»

We identified candidate predictors from the literature and input from clinicians with expertise in kidney failure and perioperative medicine. The final list of variables included demographics of age and sex. Surgeries were categorized into 11 surgery types based on CCI codes, including categories that are specific to people with kidney failure (kidney transplant, peritoneal dialysis catheter insertion, and AV fistula creation). Surgery setting was classified using the administrative data as ambulatory elective, inpatient elective, or inpatient urgent/emergent. We considered comorbidities of previous AMI, cancer, chronic pulmonary disease, dementia, diabetes, heart failure, hypertension, liver disease, obesity, peripheral vascular disease, and stroke. These were defined using validated algorithms of International Statistical Classification of Diseases and Related Health Problems Ninth and Tenth Revision (ICD-9-CM and ICD-10-CA) codes [17 (link)] with an unrestricted lookback period for permanent conditions and 3 years for temporary conditions (Supplementary Tables 3 and 4). Kidney failure treatment modality was categorized as non-dialysis, hemodialysis, or peritoneal dialysis. Preoperative outpatient serum albumin (in g/L) and serum hemoglobin (in g/L) within the year before surgery were included as candidates. There were no missing values for variables except for albumin (15%) and hemoglobin (0.2%), which were imputed using multivariable normal regression with an iterative Markov chain Monte Carlo method.
Full text: Click here
Publication 2023
Albumins Catheterization Cerebrovascular Accident Congestive Heart Failure Dementia Diabetes Mellitus Disease, Chronic Fistula, Arteriovenous Hemodialysis Hemoglobin High Blood Pressures Inpatient Kidney Kidney Failure Kidney Transplantation Liver Diseases Lung Lung Diseases Malignant Neoplasms Menstruation Disturbances Obesity Operative Surgical Procedures Outpatients Peripheral Vascular Diseases Peritoneal Dialysis Serum Serum Albumin
We included all adults (≥ 18 years) with an inpatient or ambulatory surgery performed between April 1 2005 and February 28 2019 in Alberta, Canada. Surgeries were identified using the Canadian Classification of Health Interventions (CCI) coding [14 ], which is a standardized coding system for procedures. Radiologic or non-surgical procedures were excluded (e.g., endoscopy, hemodialysis catheter insertion, arteriovenous [AV] fistulogram, etc.). Further, we included only those with preoperative kidney failure, defined as an eGFR < 15 mL/min/1.73m2 or receiving hemodialysis or peritoneal dialysis for at least 90 days as an outpatient before the index surgical procedure. For non-dialysis participants, at least two outpatient measures of serum creatinine between 7–365 days were necessary prior to surgery to avoid misclassification of people with preoperative acute kidney injury, per a validated algorithm [15 (link)]. We estimated eGFR using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation without including the Black race coefficient [16 (link)]. We excluded people that left Alberta within 30 days of their surgery, and those without available demographic data.
Full text: Click here
Publication 2023
Adult Ambulatory Surgical Procedures Catheterization Creatinine Dialysis EGFR protein, human Endoscopy Hemodialysis Inpatient Kidney Failure Kidney Injury, Acute Negroes Operative Surgical Procedures Outpatients Peritoneal Dialysis Serum
Adult patients (aged ≥18 years) with ESKD who underwent hemodialysis at King Salman Center for Kidney Disease (KSCKD) and King Fahad Medical City (KFMC), Riyadh, Saudi Arabia, between June and July 2021, and had been on dialysis for ≥1 year were included in this cross-sectional study if they consented to participate. Patients who had cognitive impairment and/or debilitating diseases (except hypertension, diabetes, and cardiovascular diseases) were excluded from the study to avoid confounding effects. This study used convenience sampling.
KSCKD is the main outpatient dialysis unit in Riyadh Second Health Cluster, and the largest dialysis center in Riyadh with a total capacity of 600 patients, and with >52,000 hemodialysis sessions per year.[12 ] The dialysis unit at KFMC, a tertiary hospital at Riyadh Second Health Cluster, has a total capacity of up to 100 patients. KSCKD and KFMC are two of the largest centers for both hemodialysis and peritoneal dialysis not only in Saudi Arabia but also in the Middle East. Therefore, the patient population undergoing in these centers is diverse and representative of the population.
Ethical approval for this study was obtained from the Institutional Review Board of KFMC. Written informed consents were obtained from the patients before participation.
Publication 2023
Adult Cardiovascular Diseases Diabetes Mellitus Dialysis Disorders, Cognitive Ethics Committees, Research Hemodialysis High Blood Pressures Kidney Diseases Outpatients Patients Peritoneal Dialysis
Preoperative factors were collected, including age, sex, recent major cardiovascular procedure (within 3 months), coronary artery disease, cerebral vascular events, chronic lung disease, essential hypertension, dyslipidemia, liver cirrhosis, atrial fibrillation, type 2 diabetes mellitus, end-stage renal disease with dialysis (both hemodialysis and peritoneal dialysis), and regular use of antiplatelet or anticoagulant agents. The major cardiovascular procedures included coronary arterial bypass, coronary arterial angioplasty/stenting, cardiac valvular surgery, aortic surgery, and peripheral arterial surgery. Preoperative blood cell counts included white cell counts, differential counts (immature band form white cell) [15 (link)], platelet counts, the neutrophil-to-lymphocyte ratio (NLR) [16 (link)], and hemoglobin levels. Preoperative blood biochemistry results included serum levels of albumin, alanine aminotransferase (ALT), bilirubin, and creatinine. The coagulation test included the prothrombin time (PT) and was expressed by the international normalized ratio (INR). Preoperative shock status was defined as the requirement for vasopressors or inotropes. The types of AMI were determined by preoperative contrast CT scans.
Full text: Click here
Publication 2023
Angioplasty Angioplasty, Balloon, Coronary Anticoagulants Aorta Arteries Artery, Coronary Atrial Fibrillation Bilirubin BLOOD Cardiovascular System Cells Cerebrovascular Accident Coronary Arteriosclerosis Coronary Artery Bypass Surgery Creatinine D-Alanine Transaminase Diabetes Mellitus, Non-Insulin-Dependent Dialysis Disease, Chronic Dyslipidemias Essential Hypertension Hemodialysis Hemoglobin Inotropism International Normalized Ratio Kidney Failure, Chronic Leukocyte Count Liver Cirrhosis Lung Lung Diseases Lymphocyte Neutrophil Neutrophil Band Cells Operative Surgical Procedures Peritoneal Dialysis Platelet Counts, Blood Serum Albumin Shock Surgical Procedure, Cardiac Tests, Blood Coagulation Times, Prothrombin Vasoconstrictor Agents X-Ray Computed Tomography
Male C57BL mice (purchased from Shanghai Super-B&K Laboratory Animal Corp. Ltd) weighed 20-25g were used in this study. The peritoneal fibrosis model was created by daily i.p. injection of 100 ml/kg peritoneal dialysis fluid with 4.25% glucose for 28 days (6 (link)). To examine the efficacy of PCI-34051 in peritoneal fibrosis, two different concentrations of PCI-34051 (10 or 20 mg/kg) in DMSO was intraperitoneally every day and the mice were sacrificed on day 28 to collect peritoneum. The animal protocol was reviewed and approved by the Institutional Animal Care and Use Committee at Tongji University (Shanghai, China). The details of animals and treatment are provided in the Supplementary Material and Methods.
Full text: Click here
Publication 2023
Animals Animals, Laboratory Glucose Institutional Animal Care and Use Committees Males Mice, House Mice, Inbred C57BL PCI 34051 Peritoneal Dialysis Peritoneal Fibrosis Peritoneum Sulfoxide, Dimethyl

Top products related to «Peritoneal Dialysis»

Sourced in United States, China, Singapore, Ireland
Dianeal is a sterile, nonpyrogenic peritoneal dialysis solution used for the treatment of end-stage renal disease. It is designed to facilitate the removal of waste products and excess fluid from the body through the peritoneal membrane. The solution contains electrolytes and dextrose to maintain the appropriate fluid and electrolyte balance.
Sourced in United States, United Kingdom, Germany, China
BNT162b2 is a vaccine candidate developed by Pfizer and BioNTech. It is a messenger RNA (mRNA) vaccine that encodes the SARS-CoV-2 spike protein. The core function of BNT162b2 is to induce an immune response against the SARS-CoV-2 virus.
Sourced in United States, United Kingdom, Denmark, Austria
Stata is a general-purpose statistical software package for data analysis, data management, and graphics. It provides a wide range of data manipulation, statistical, and graphical tools to help researchers and analysts effectively analyze and visualize data.
Sourced in United States, United Kingdom
MRNA-1273 is an mRNA-based vaccine candidate developed by Moderna. It is designed to encode the prefusion stabilized full-length spike protein of SARS-CoV-2. The core function of MRNA-1273 is to generate an immune response against the SARS-CoV-2 virus.
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
Sourced in China
Peritoneal dialysis fluid is a sterile solution used in the process of peritoneal dialysis. It is designed to facilitate the exchange of waste and excess fluids from the patient's bloodstream through the peritoneal membrane in the abdomen. The composition of the fluid is formulated to provide the necessary electrolytes and osmotic agents required for effective dialysis.
Sourced in United States, United Kingdom, Germany, Macao, China, Sao Tome and Principe, Japan, Italy, Israel
α-SMA is a common marker for the identification of activated myofibroblasts. It is a contractile protein that is expressed in smooth muscle cells and myofibroblasts. α-SMA is often used in research applications to study fibrosis and tissue remodeling.
Sourced in United States, Japan, United Kingdom, Germany, Belgium, Austria, Italy, Poland, India, Canada, Switzerland, Spain, China, Sweden, Brazil, Australia, Hong Kong
SPSS Statistics is a software package used for interactive or batched statistical analysis. It provides data access and management, analytical reporting, graphics, and modeling capabilities.
Sourced in China, United States
Peritoneal dialysis solution is a sterile, isotonic solution used in peritoneal dialysis, a type of dialysis treatment for kidney failure. The solution is designed to be infused into the patient's peritoneal cavity, where it facilitates the removal of waste and excess fluid from the body.
Sourced in United States
Dianeal® PD-2 1.5% peritoneal dialysis solution is a sterile, nonpyrogenic solution for use in peritoneal dialysis. It contains dextrose monohydrate, sodium chloride, calcium chloride, magnesium chloride, and purified water.

More about "Peritoneal Dialysis"

Peritoneal dialysis (PD) is a form of renal replacement therapy that uses the patient's peritoneal membrane as a natural filter to remove waste, excess water, and other substances from the body.
This procedure is often employed for individuals with end-stage renal disease (ESRD) or kidney failure, as it allows for more frequent dialysis sessions that can be performed at home.
The process involves introducing a sterile dialysis solution, known as Dianeal® PD-2 1.5% peritoneal dialysis solution, into the peritoneal cavity.
This solution then absorbs waste products, such as urea and creatinine, as well as excess water, from the blood.
After a specified period, the used solution is drained and replaced with fresh solution, allowing the cycle to repeat.
Optimizing peritoneal dialysis research is crucial for improving patient outcomes.
Tools like PubCompare.ai can help researchers effortlessly locate, compare, and analyze the latest protocols from literature, preprints, and patents to identify the best dialysis products and procedures.
This can include evaluating the efficacy of different dialysis solutions, such as the Dianeal PD-2 1.5% solution, as well as assessing the impact of various factors on patient outcomes, such as the use of α-SMA (alpha-smooth muscle actin) biomarkers.
Researchers may also utilize statistical software like Stata, SAS version 9.4, or SPSS Statistics to analyze data and evaluate the performance of peritoneal dialysis treatments, including the efficacy of mRNA-based therapies like BNT162b2.
By leveraging these tools and resources, the peritoneal dialysis research community can work towards improving the quality of life and outcomes for patients with ESRD.